A novel GABRB3 variant in Dravet syndrome: Case report and literature review.


Journal

Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758

Informations de publication

Date de publication:
11 2020
Historique:
received: 18 05 2020
revised: 31 07 2020
accepted: 31 07 2020
pubmed: 19 9 2020
medline: 8 6 2021
entrez: 18 9 2020
Statut: ppublish

Résumé

Mutations in GABRB3 have been identified in subjects with different types of epilepsy and epileptic syndromes, including West syndrome (WS), Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), myoclonic-atonic epilepsy (MAE), and others. We herewith report on a girl affected by DS, who has been followed from infancy to the current age of 18 years. Next-generation sequencing (NGS)-based genetic testing for multigene analysis of neurodevelopmental disorders identified two likely de novo pathogenic mutations, a missense variant in GABRB3 gene (c.842 C>T; p.Thr281IIe) and a nonsense variant found in BBS4 gene (c.883 C>T; p.Arg295Ter). A likely relationship between the novel GABRB3 gene variant and the clinical manifestations presented by the girl is proposed. Previously, one case of DS and two of DS-like linked with GABRB3 mutations have been reported. To the best of our knowledge, this is the first report of DS associated with this novel variant. A literature review of clinical cases with various types of epileptic encephalopathies (EEs) related to GABRB3 mutations is reported.

Sections du résumé

BACKGROUND
Mutations in GABRB3 have been identified in subjects with different types of epilepsy and epileptic syndromes, including West syndrome (WS), Dravet syndrome (DS), Lennox-Gastaut syndrome (LGS), myoclonic-atonic epilepsy (MAE), and others.
METHODS AND RESULTS
We herewith report on a girl affected by DS, who has been followed from infancy to the current age of 18 years. Next-generation sequencing (NGS)-based genetic testing for multigene analysis of neurodevelopmental disorders identified two likely de novo pathogenic mutations, a missense variant in GABRB3 gene (c.842 C>T; p.Thr281IIe) and a nonsense variant found in BBS4 gene (c.883 C>T; p.Arg295Ter).
CONCLUSION
A likely relationship between the novel GABRB3 gene variant and the clinical manifestations presented by the girl is proposed. Previously, one case of DS and two of DS-like linked with GABRB3 mutations have been reported. To the best of our knowledge, this is the first report of DS associated with this novel variant. A literature review of clinical cases with various types of epileptic encephalopathies (EEs) related to GABRB3 mutations is reported.

Identifiants

pubmed: 32945607
doi: 10.1002/mgg3.1461
pmc: PMC7667356
doi:

Substances chimiques

BBS4 protein, human 0
Codon, Nonsense 0
GABRB3 protein, human 0
Microtubule-Associated Proteins 0
Receptors, GABA-A 0

Types de publication

Case Reports Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1461

Informations de copyright

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Références

Neurology. 2016 Sep 13;87(11):1140-51
pubmed: 27521439
Epilepsia. 2017 Feb;58(2):e26-e30
pubmed: 28084635
J Child Neurol. 2016 Mar;31(4):523-32
pubmed: 26271793
PLoS Genet. 2014 Oct 30;10(10):e1004772
pubmed: 25356899
J Physiol. 2010 Jun 1;588(Pt 11):1861-9
pubmed: 20308251
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Epilepsia. 2017 Apr;58(4):512-521
pubmed: 28276062
Neurology. 2017 Jan 31;88(5):483-492
pubmed: 28053010
Obes Res. 1995 Jul;3(4):387-99
pubmed: 8521156
Dev Med Child Neurol. 2016 Apr;58(4):416-20
pubmed: 26645412
Obes Res. 1995 Jul;3(4):404
pubmed: 8521158
Neuropediatrics. 2018 Jun;49(3):204-208
pubmed: 29444535
Nature. 2013 Sep 12;501(7466):217-21
pubmed: 23934111
Am J Hum Genet. 2019 Aug 1;105(2):267-282
pubmed: 31327507
Mol Genet Genomic Med. 2020 Nov;8(11):e1461
pubmed: 32945607
Am J Med Genet A. 2017 Aug;173(8):2126-2131
pubmed: 28544625
Brain. 2017 Nov 1;140(11):2879-2894
pubmed: 29053855
Eur J Med Genet. 2015 Dec;58(12):689-94
pubmed: 26518167
Semin Pediatr Neurol. 2017 Nov;24(4):251-263
pubmed: 29249505
Prog Brain Res. 2014;213:55-85
pubmed: 25194483
Brain. 2019 Oct 1;142(10):3028-3044
pubmed: 31435640

Auteurs

Piero Pavone (P)

Unit of Pediatrics and Pediatric Emergency, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.

Xena Giada Pappalardo (XG)

National Council of Research, Institute for Biomedical Research and Innovation (IRIB), Unit of Catania, Italy.
Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, Italy.

Simona D Marino (SD)

Unit of Neonatology University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.

Laura Sciuto (L)

Unit of Pediatrics and Pediatric Emergency, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.

Giovanni Corsello (G)

Department of Sciences for Health Promotion and Mother and Child Care "G. D'Alessandro", University of Palermo, Italy.

Martino Ruggieri (M)

Unit of Pediatrics and Pediatric Emergency, University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.

Enrico Parano (E)

National Council of Research, Institute for Biomedical Research and Innovation (IRIB), Unit of Catania, Italy.

Maria Piccione (M)

Department of Sciences for Health Promotion and Mother and Child Care "G. D'Alessandro", University of Palermo, Italy.

Raffaele Falsaperla (R)

Unit of Neonatology University Hospital "Policlinico-Vittorio Emanuele", Catania, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH